---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016500"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:23:24.139751+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaxart appoints Jeroen Grasman as CFO, replaces Phillip Lee

## Summary
- CFO Phillip Lee resigns effective upon appointment of successor; no disagreement; remains as non-executive employee through June 1, 2025.
- Jeroen Grasman appointed CFO effective May 19, 2025; previously CFO at AltruBio, VP Finance at PACT Pharma and Genentech.
- Grasman receives base salary $435K, target bonus 40%, option for 1M shares vesting over 48 months, RSU for 350K shares.
- Lee forfeits unvested equity upon termination; no termination benefits.

## SEC filing metadata
- accession: 0001437749-25-016500
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925016500/0001437749-25-016500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925016500/vxrt20250513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016500
- JSON: https://secwatch.observer/filing/0001437749-25-016500.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016500.txt

## Key facts
- Executive change
  Jeroen Grasman was appointed as Chief Financial Officer at Vaxart, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 13, 2025, the Company announced that its Board of Directors had appointed Jeroen Grasman to serve as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective as of May 19, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774925016500/0001437749-25-016500-index.htm
- Executive change
  Phillip Lee resigned as Chief Financial Officer at Vaxart, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 12, 2025, Phillip Lee notified the Company of his intention to resign as the Chief Financial Officer of Vaxart, Inc. (the “Company”) and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective upon the appointment of a new Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774925016500/0001437749-25-016500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.